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E6 and E7 oncoproteins of human papillomavirus
(HPV) play significant roles in the pathogenesis of
cervical cancer. However, the pattern of E6/E7
expression during the productive virus life cycle in
differentiating epithelia of the uterine cervix
remains unclear. In addition, little is known about
the cellular factors regulating E6/E7 expression in
differentiating epithelia. In the present study, using
transient expression assays and DNA binding as-
says, we demonstrated that E6/E7 transcription is
critically regulated by the cellular factor AP1, a
Jun/Fos heterodimer complex. Immunohistochem-
ical analyses of various uterine cervical lesions
showed AP1 expression in lower cell layers of
normal cervix and low-grade cervical intraepithelial
neoplasia (CIN), while it was detected throughout all
layers in high-grade CIN and invasive cancer. In situ
Introduction
Among over 70 different types of human papillomavirus
(HPV) identified, several, including HPV-16, -18, -31,
-33, -52 and -58, are associated with cervical cancer (zur
Hausen, 1989) and designated as high-risk types. Genetic
analyses of high-risk HPVs have revealed two transforming
genes (E6 and E7) which remain intact and are actively
transcribed in cervical cancers (Baker et al., 1987 ; Schwartz et
al., 1985 ; Yutsudo et al., 1988). E6 and E7 oncoproteins of
high-risk HPVs have been shown to bind tumour suppressor
gene products, impairing their normal functions (Scheffner et
al., 1990 ; Werness et al., 1990). These observations strongly
suggest that the E6 and E7 genes play significant roles in the
pathogenesis of cervical cancer.
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RNA–RNA hybridization analyses of organotypic
raft culture specimens of an HPV-31-containing cell
line revealed that E6/E7 transcripts were expressed
in most cell layers, with reduced expression in
differentiated cells. This pattern of HPV expression
correlated with the pattern of AP1 expression
detected by immunohistochemical analyses. These
findings suggest that E6/E7 expression in differ-
entiating epithelia is dependent on AP1, which
appears to be associated with proliferative activity
of the cells. Since E6/E7 expression induces cell
proliferation, co-expression of AP1 and E6/E7 in
undifferentiated cell layers might create a positive
regulatory loop, probably contributing to main-
tenance of initial HPV infection and subsequent
activation in basal and suprabasal cell layers.
E6 and E7 genes are transcribed from the HPV early
promoter, which is designated p97 in HPV-16 and HPV-31
and p105 in HPV-18. The activity of this promoter is regulated
by transcriptional control elements in the long control region
(LCR), which is located upstream of the start site (Gloss et al.,
1987). Several nuclear factors have been shown to bind the
LCR at specific sites and regulate the transcriptional activity of
the promoter, leading to keratinocyte-specific transcriptional
activation of HPV. The factors that regulate expression seem
to be different among HPV types, suggesting diverse mech-
anisms of activation. For HPV-16, the factors AP1, NF1, TEF-
1, TEF-2 and Oct1 have all been implicated in transcriptional
regulation (Chan et al., 1990 ; Chong et al., 1991 ; Ishiji et al.,
1992). In contrast, for HPV-18 a keratinocyte-specific factor,
KRF-1, has been reported to interact with AP1 to activate
transcription (Butz & Hoppe-Seyler, 1993 ; Mack & Laimins,
1991). No significant activities of NF1 or Oct1 have been
demonstrated in this HPV type. We have previously shown
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that AP1 interacts synergistically with two novel factors to
achieve full activation of HPV-31b transcription (Kyo et al.,
1995). These novel factors were found to be distinct from any
of those that regulate either HPV-16 or -18 expression. Taken
together, AP1 appears to be a common regulator of expression
for various HPV types while additional HPV type-specific
cellular factors may be required to cooperate with AP1 to
achieve full activation of virus gene expression.
HPVs exhibit a complex pattern of expression during a
productive infection in differentiating epithelia. Following
infection in stratified epithelial cells, HPV genomes are
maintained as low copy number episomes in basal cells. As
infected cells migrate from the basal layer and undergo
differentiation, late gene expression is activated and virus
DNA is amplified (Bedell et al., 1991 ; Laimins, 1993). Numerous
studies have identified L1}L2 late transcripts of HPVs in the
differentiated cell layers of the epithelia (Broker et al., 1989 ;
Crum et al., 1988 ; Higgins et al., 1992). It is likely that increased
expression of late transcripts and amplification of HPV
genomes result in the assembly of virus particles. While the
distribution of late gene expression is well characterized, it is
still unclear how early gene expression is modulated during the
productive infectious cycle in differentiating epithelia. Using
RNA in situ hybridization of genital condyloma and cervical
intraepithelial neoplasia (CIN) grade I tissues, several studies
reported that E6}E7 transcripts were most highly expressed in
the superficial layers, suggesting differentiation-dependent
expression of E6}E7 (Broker et al., 1989 ; Chow et al., 1987 ;
Stoler et al., 1989). Other analyses using CIN I tissue
demonstrated that E6 transcripts were expressed throughout
all layers (Higgins et al., 1992).The actual distribution of E6}E7
expression is therefore unclear. The role of AP1 in E6}E7
expression in differentiating epithelia also remains unclear.
In the present study, we first confirmed that AP1 is a
predominant determinant of HPV-31b enhancer activity which
directs E6}E7 transcription. All of the Jun family members
were found to bind and transactivate HPV expression,
probably contributing to the cell-type specificity of HPV
transcription. Using in situ RNA hybridization analyses of
stratified raft cultures of CIN612 cells, E6}E7 transcripts were
found to be expressed in most cell layers with a reduced level
of expression in differentiated cells. Expression was also shown
to correlate with distribution of AP1 factors. These findings
suggest that AP1 plays a significant role in the expression of
E6}E7 in differentiating epithelia of the uterine cervix.
Methods
+ Cell culture. C33A, Hs68 and HepG2 cells were grown in
Dulbecco’s modified Eagle’s medium supplemented with 10% foetal calf
serum in the presence of 5% CO
#
. SCC13 cells and CIN612 cells were
grown in E medium with mitomycin C-treated fibroblast feeders as
described previously (McCance et al., 1988). BJAB cells were grown in
RPMI-1640 medium supplemented with 10% foetal calf serum. Collagen
raft cultures of CIN612 cells for in vitro differentiation were prepared as
described previously (McCance et al., 1988).
+ Plasmids. Reporter plasmids containing the whole LCR of HPV-
31b were constructed for use in transient expression assays. HPV-31b
LCR (nucleotide 6920–117)-containing p97 early promoter was cloned
upstream of the luciferase gene in pGL2-Basic plasmid (Promega). For the
construction of reporter plasmids containing substitution mutations in
AP1 sites in the HPV-31b LCR, site-specific mutagenesis was performed
by a PCR-based protocol (Higuchi, 1990). All the mutated plasmids were
sequenced to confirm the presence of the expected mutations. A reporter
plasmid containing the whole LCR fragment of HPV-18 was a kind gift
from F. Hoppe-Seyler (German Cancer Research Centre, Heidelberg,
Germany ; Butz & Hoppe-Seyler, 1993). JunB, c-Jun, JunD and c-Fos
expression vectors were a kind gift from M. Yaniv (Institut Pasteur, Paris
cedex, France ; Hirai et al., 1990).
+ Immunohistochemistry. Expression of AP1 was determined
immunohistochemically by the avidin–biotin–peroxidase method using
10% formalin or 4% paraformaldehyde-fixed and paraffin-embedded
sections. Briefly, the tissue sections were deparaffinized, hydrated in
graded ethanol and immersed for 20 min in 0±3% hydrogen peroxide
to block endogenous peroxidase activity. The slides were washed in PBS
pH 7±4 and treated with protease E at a final concentration of 0±1 mg}ml
for 20 min at 37 °C. After washing with PBS, slides were treated with
10% normal goat serum for 20 min to inhibit non-specific binding to
antisera. Primary antibodies against Jun family members (anti-JunB, SC-
g46 ; anti-c-Jun, SC-g45 ; anti-JunD, SC-g74 Santa Cruz) were applied to
the sections at a final concentration of 0±2 lg}ml for 1 h at room
temperature. After rinsing in PBS, the sections were incubated for 30 min
with biotin-labelled anti-rabbit IgG (Vector). They were then treated with
the avidin–biotin complex (Vector) at room temperature. Negative
controls included sections incubated with normal goat serum instead of
the primary specific antibody. Sites of peroxidase activity were visualized
with DAB substrate kit (Vector).
+ Transient expression assay. Five to 10 lg of luciferase reporter
plasmids were co-transfected with 2 lg of SV2 b-galactosidase plasmid
and various amounts of effector plasmids into cultured cells by the
calcium phosphate method (for HeLa, C33A cells and HepG2 cells),
lipofection (primary foreskin keratinocytes) or electroporation (CIN612
and BJAB) as described previously (Ustav & Stenlund, 1991). At 48 h
after transfection, cells were harvested and luciferase assays were
performed according to the protocols of the Promega Luciferase Assay
system. Luciferase activity was normalized to b-galactosidase activity to
correct for transcription efficiency in each reaction.
+ Electrophoretic mobility shift assay (EMSA). Nuclear extracts
were prepared from a variety of cell types as previously described
(Schreiber et al., 1989). Five to 10 lg of nuclear extracts were incubated
with 2 lg of poly(dI–dC) in the presence or absence of a 100-fold molar
excess of unlabelled competitor DNAs on ice for 20 min in a 25 ll
reaction volume containing 10% glycerol, 25 mM HEPES pH 7±9, 50 to
100 mM KCl, 4 mM MgCl
#
and 0±5 mM PMSF. Following incubation,
10000 c.p.m. of $#P end-labelled oligonucleotide probe was added and
the reaction incubated at room temperature for an additional 30 min. The
DNA–protein complexes were then separated from free probe by
electrophoresis on a 4% polyacrylamide gel at 4 °C. The gel was dried
and subjected to autoradiography. For supershift analyses, nuclear
extracts were preincubated with specific antibodies for 60 min at 4 °C
and then used for EMSA. For competition assays, consensus binding sites
for AP1 (5« CGCTTGATGAGTCAGCCGGAA 3«), Oct1 (5«
TGTCGAATGCAAATCACTA 3«) and TEF-1 (5« CTAGATGCATGC-
TTTGCATACTTCTGCCTAG 3«) (Promega) were used as competitors.
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+ DNase I footprint analysis. The binding reaction for footprint
analysis was the same as that used for EMSA except that the reaction
volume was 50 ll. The probe used was a 262 bp fragment (nucleotides
7511–7772) of HPV-31b upstream regulatory region, which was end-
labelled with $#P. Following incubation of the probe with the extract,
DNase I was added at a final concentration of 30 to 45 U}ml and the
samples were further incubated at room temperature for 1 min. The
reaction was stopped by adding 100 ll of stop buffer containing 100 mM
Tris–HCl pH 8±0, 100 mM NaCl, 1% sodium sarcosyl, 10 mM EDTA and
25 lg sonicated salmon sperm DNA per ml. Following two phenol–
chloroform extractions, the DNA was ethanol-precipitated. The pellets
were then redissolved, denatured and electrophoresed on denaturing 6 or
8% polyacrylamide gels. The gels were dried and examined by
autoradiography. Chemically cleaved DNAs were used as sequence
markers.
+ In situ RNA–RNA hybridization. Raft culture tissue sections em-
bedded in paraffin were dewaxed, rehydrated and denatured in 0±2 M
HCl at room temperature for 20 min and in 2¬SSC at 70 °C for 15 min.
After washing with PBS, the specimens were fixed with 4% para-
formaldehyde followed by blocking with 10 mM DTT, iodoacetamide
and N-acetylmaleimide, and dehydrated. Using an in vitro RNA
transcription system (Stratagene), the probes for the E6}E7 region of
HPV-31b were synthesized with $#P-labelled UTP from inserts spanning
nucleotides 200 to 747 in the E6}E7 ORF, which was cloned into vectors
(pBluescript) containing both T3 and T7 polymerase binding sites.
Transcription by the T3 polymerase therefore generated anti-sense
probes. The probes were added in a hybridization mixture containing
50% formamide, 0±3 M NaCl, 10 mM Tris–HCl pH 8±0, 1 mM EDTA,
1¬Denhardt’s solution, 500 lg}ml of yeast tRNA, 500 lg}ml of poly(A)
(Pharmacia), 50 mM DTT and 10% PEG (EM Science) to obtain a
0±3 lg}ml final probe concentration. Hybridization was performed by
spreading the probe mixture on the specimens and incubating at 45 °C in
a moist chamber for 4 h. After hybridization, specimens were washed at
55 °C twice each in wash solution A (50% formamide, 2¬SSC, 20 mM
2-mercaptoethanol), B (50% formamide, 2¬SSC, 20 mM 2-mercapto-
ethanol, 0±5% Triton X-100) and C (2¬SSC, 20 mM 2-mercapto-
ethanol). The specimens were then treated with RNase solution
containing 40 lg}ml of RNase A (Sigma) and 2 lg}ml of RNase T1
(Sigma), 10 mM Tris–HCl pH 7±5, 5 mM EDTA and 0±3 M NaCl for
15 min at room temperature, followed by washing at 50 °C twice each in
wash solution C and A. They were then rinsed with 2¬SSC at room
temperature and air-dried. Emulsion autoradiography was performed to
detect the signals.
Results
E6/E7 transcription is dependent on AP1 activity in a
variety of cell types
AP1 is a significant determinant of enhancer activity of HPV-31.
We first confirmed the cell type-specificity of the HPV-31
enhancer and promoter using transient expression assays.
Luciferase reporter plasmids containing the enhancer–
promoter sequence in its natural context in the HPV-31b LCR
were transfected into a variety of cell types and luciferase
assays were performed. As expected, LCR activity was found
to be the highest in the cell lines derived from keratinocytes
such as CIN612, primary foreskin keratinocytes and HeLa cells,
whereas reduced expression was observed in non-keratinocyte
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Fig. 1. (a) Luciferase assay to examine the cell type-specificity of the HPV
promoter. Luciferase reporter plasmids were transfected into a variety of
cell types. At 48 h after transfection, cells were collected and luciferase
assays were performed. Luciferase activity was normalized by that of a
negative control in which cells were transfected with the reporter plasmid
containing no enhancer–promoter sequence. PHK, primary foreskin
keratinocyte. (b) DNase I footprint analysis to identify the factor binding
sites within the HPV-31b minimum enhancer. A 262 bp fragment
(nucleotides 7511–7772) of the HPV-31 enhancer was end-labelled with
32P and incubated with extracts from HeLa (i), CIN612 or C33A cells (ii)
followed by the treatment with DNase I. In (®) lanes, no nuclear extract
was added. Five protected sequences were identified and are shown as
boxes, designated FPI to V. FPV was on the edge of the enhancer and is
not shown.
(lymphoid cell origin) (Fig. 1a), suggesting the keratinocyte-
specific transactivation of HPV early genes from the hom-
ologous promoter. Surprisingly, transcriptional activity was
quite low in C33A cells despite the fact that these cells were of
keratinocyte origin. Similar results were obtained using an
HPV-18 LCR reporter plasmid. To examine further the reasons
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Fig. 2. Luciferase assays to determine the functional significance of AP1 sites in the HPV-31b LCR. Four AP1 sites designated
AP1-1, AP1-2, AP1-3 and AP1-4 are shown as well as their core sequences similar to the AP1 consensus motif. Substitution
mutations introduced are also shown. Luciferase reporter plasmids containing the whole LCR of HPV-31b with or without
mutations in the core sequences of each AP1 site were transfected into HeLa cells or CIN612 cells and luciferase assays were
performed. Relative luciferase activity in each plasmid is shown.
for this cell type-dependent expression, footprint analyses
were performed in the HPV-31b enhancer region using nuclear
extracts from HeLa, CIN612 and C33A cells. As reported
previously (Kyo et al., 1995), a series of protected sequences
were identified in the minimum enhancer region of HPV-31b
with HeLa nuclear extracts, designated FPI to V, respectively.
Fig. 1 (b) shows protected sequences FPI to IV ; FPV was
located at the end of the probe. In the previous study, we
demonstrated that FPI and II, and FPV had similarities to NF1
and KRF-1 sites, respectively, but that they bound novel
factors. FPIII was found to bind AP1, and FPIV bound AP1 as
well as Oct1. Similar patterns of footprints were also observed
using extracts from HPV-31b-positive CIN612 cells. However,
when extracts from C33A cells were used, FPIII and IV
footprints were diminished while FPI and II (Fig. 1b) as well as
FPV (data not shown) remained significant. These findings
suggested that a reduction in AP1 binding activity in C33A
cells might contribute to the decreased activity of the HPV
enhancer.
Four AP1 sites in the HPV-31 LCR function synergistically for full
activation of the enhancer. Initial analysis of the HPV-31
enhancer region (nucleotides 7511–7772) identified two AP1
sites corresponding to FPIII and IV (designated AP1-1 and
AP1-2, respectively ; Kyo et al., 1995). Computer-assisted
analysis of the entire LCR suggested two other putative sites
for AP1 outside the enhancer, designated AP1-3 and AP1-4,
both of which contained sequences similar to the AP1
consensus motif (7805–7811 and 7835–7841) (Fig. 2). These





















































Fig. 3. EMSA to confirm the AP1 binding to the putative AP1 sites outside
the enhancer of HPV-31b LCR. Nuclear extracts from HeLa cells were
incubated with 32P-labelled probes for AP1-3 (a) and AP1-4 (b) sites in
the presence of the various competitors shown above each lane. NS
represents non-specific binding. AP1-3MT and AP1-4MT represent
oligonucleotides containing substitution mutations in core sequences of
AP1-3 and AP1-4 probes, respectively. The sequences of probes and
competitors used are shown in Methods and Table 1.
transcription, indicating that they form part of the LCR
promoter. AP1 binding to these sites was confirmed by EMSA.
As shown in Fig. 3, specific binding was observed to both sites,
EAE













































Fig. 4. EMSA showing the binding of Jun members to HPV-31b enhancer in a variety of cell types. Nuclear extracts from
CIN612 (a), Hs68 (b) and SCC13 (c) cells were pre-incubated with antibodies against JunB, c-Jun, JunD and Fos as indicated
above each lane and then incubated with FPIII probe containing an AP1-1 site. In the control sample, antibody against SP1 was
pre-incubated with extracts. NS represents non-specific binding. Multiple bands were observed in SCC13 cells and only the




















































Fig. 5. Induction of AP1 in the cells in which HPV enhancers are inactive. Expression plasmids for JunB, c-Jun and JunD were
each co-transfected with c-Fos expression plasmids as well as a luciferase reporter plasmid containing the wild-type LCR of
HPV-31b into C33A (a) and HepG2 (b) cells and transient expression assays were performed. In control samples, SV2-Neo
plasmid was co-transfected with a reporter plasmid . At 48 h after transfection, cells were collected and luciferase assays were
performed.
which was diminished by addition of the AP1 consensus motif
but not by addition of unrelated sequences or oligonucleotides
containing substitution mutations in their AP1-like consensus
motifs, suggesting that AP1 binds to these sites. Additional
interactions were observed with the AP1-3 and AP1-4 sites,
which were competed by addition of Oct1 and TEF-1
consensus motifs, respectively, suggesting that Oct1 and TEF-
1 factors also bind these sites. We next sought to examine the
functional significance of the AP1 sites. Luciferase reporter
plasmids containing substitution mutations in each AP1 site
were transfected into HeLa or CIN612 cells and luciferase
assays were performed (Fig. 2). Mutations introduced are
shown in Fig. 2 and Table 1. They were confirmed to abrogate
AP1 binding in our previous study (Kyo et al., 1995) and by
EMSA in the present study. In HeLa cells, each mutation
resulted in an 80 to 90% reduction in luciferase activity,
showing the drastic effect of AP1 factors on HPV-31
transcription. Similarly, in CIN612 cells, mutation of AP1-1
EAF






Fig. 6. Immunohistochemical analysis to identify AP1 expression in the stratified epithelia of normal cervix (a), CIN II (b) and
CIN III (c). Bar marker represents 200 lm. Sections were incubated with normal goat serum for controls (i) or with primary
antibodies against JunB (ii), c-Jun (iii) or JunD (iv). Arrows indicate significant AP1 signals.
had a severe effect while disruption of AP1-2, AP1-3 and AP1-
4 had a less severe effect. These data suggest that AP1 sites
outside the minimum enhancer also contribute to LCR
transcription. Since each mutation was effective independent of
the other sites, it appears that these sites function synergisti-
cally for full activation of enhancer.
Differential effect of each Jun type on the HPV enhancer in
different cell types. To examine the distribution of Jun family
members in a variety of cell types and to identify the
predominant Jun type binding to the HPV-31 LCR, an EMSA
was performed using an AP1 site (AP1-1) as a probe with
nuclear extracts from different cell types (Fig. 4). In CIN612
EAG
















Fig 7. (a) Probe sequences used in in situ mRNA hybridization. The p97 early promoter of HPV-31b is shown. The p742 E7
promoter which directs E1gE4 differentiation-dependent transcripts is also indicated. (b) Immunohistochemical analysis to
identify AP1 expression in the differentiating epithelia of organotypic raft cultures using CIN612 cells. Sections were incubated
with normal goat serum for controls (i) or with primary antibodies against JunB (ii), c-Jun (iii) and JunD (iv). Bar marker
represents 200 lm. (c) In situ mRNA hybridization to detect HPV-31b E6/E7 signals in raft tissues. Sections were hybridized
with sense probes (i) or anti-sense probe (ii). Bar marker represents 200 lm. Arrows indicate terminally differentiated layers.
cells, an AP1-specific shifted band was observed and it was
significantly reduced following incubation with a JunD anti-
body, while it was only moderately inhibited by addition of
JunB and c-Jun antibodies. A different spectrum of inhibition
was observed in Hs68 cells, where the shifted band was
completely inhibited by addition of c-Jun antibody but
moderately competed by addition of JunD antibody. No
change was observed on addition of JunB antibody. In the
EAH
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Table 1. Oligonucleotides used for Electrophoresis Mobility Shift Assay
Name          Position (nt)             Sequence*
AP1-1        7636–7660
AP1-3        7796–7822
AP1-3MT    7796–7822
AP1-4        7825–7851
AP1-4MT   7825–7851
*  Mutations introduced are underlined.
squamous cancer cell line SCC13, which lacks HPV sequences,
the AP1 shift was equally inhibited by addition of each
antibody. These results suggest that each of the Jun members
can bind the AP1 sites in the HPV-31 LCR but the predominant
type appears to vary between different cell types.
We next sought to determine if there was any functional
difference between the Jun types in transactivation of the HPV-
31 LCR. Three types of Jun expression plasmids (junB, c-jun
and junD) were each co-transfected with c-fos expression
plasmids and a luciferase reporter plasmid containing the HPV-
31b LCR into C33A cells or HepG2 cells. Transient expression
assays were then performed. These cells exhibited low levels of
HPV-31 expression in transient assays (Fig. 1a). As shown in
Fig. 5, in C33A cells, co-transfection of c-jun and c-fos led to an
activation of 15-fold above background, while cotransfection
of fos with junB and junD increased expression six- and fivefold,
respectively. In HepG2 cells, transfection of junB increased
expression 12-fold, while c-jun and junD activated expression
10-fold. Expression of each Jun member without co-expression
of Fos had only marginal effects (data not shown). These
findings suggest that each Jun family member is capable of
activating HPV expression in cooperation with Fos, though
there was some preferred activity in different cell lines. These
studies also demonstrate that HPV expression can be increased
by higher levels of AP1 factors, indicating that the levels of
these proteins can contribute to the transcriptional activity of
HPV.
Expression of the Jun family in stratified epithelia of
the uterine cervix
To characterize the distribution of Jun family members in
stratified epithelial cells of uterine cervix, immunohistochemical
analyses were performed using JunB, c-Jun and JunD antibodies
with paraffin-embedded biopsy specimens from normal cervix,
various degrees of CIN and cervical cancer. Representative
results are shown in Fig. 6. In normal cervix and low-grade CIN
II, which retain markers of terminal differentiation, JunB and
JunD were mainly expressed in the basal cell and suprabasal
cell layers, although faint signals were observed in more
differentiated layers. No expression was observed in the most
terminally differentiated layers. It thus appeared that JunB and
JunD were preferentially expressed throughout lower layers of
the epithelia. c-Jun expression was mainly observed in the
lower layers but weak signals were also observed in more
differentiated layers. In contrast, in high-grade CIN and
invasive cancer, which are composed of undifferentiated cells,
AP1 expression was observed throughout the layers and a
similar distribution was observed for all three Jun family
members
E6/E7 and AP1 expression in an in vitro differentiation
system
We next sought to investigate how HPV early gene
expression was regulated during the virus life cycle in
differentiating epithelia, using an in vitro raft system for
epithelial differentiation with CIN612 cell lines containing
HPV-31b genomes as episomes. Organotypic raft cultures
using CIN612 cells stratify in a manner similar to that seen in
low-grade CIN lesions and are able to synthesize HPV-31
virions (Myer et al., 1992). The probe used in this study was
designed based on our previous analyses of the late promoter
that directs synthesis of the E1–E4 transcript of HPV-31b
(Hummel et al., 1992). The probe includes sequences from E6
and stops at nucleotide 745 in the E7 ORF, and does not
contain sequences from the E1–E4 differentiation-dependent
transcript (Fig. 7a).
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In situ mRNA hybridization using this probe revealed that
E6}E7 transcripts were distributed in both the basal and
suprabasal regions and at a lower level in the more differen-
tiated cells (Fig. 7 c). Only faint signals were observed in the
terminally differentiated superficial layers. These signals were
specific for HPV early transcripts because control specimens
hybridized with sense probe gave no significant signal. When
immunohistochemical analysis of jun expression was perform-
ed using rafts of CIN612 cells, we observed a similar
distribution of expression to that seen in biopsy materials and
a strong correlation with HPV-31 early gene expression (Fig.
7b). These findings demonstrated that E6}E7 expression was
closely associated with AP1 expression and further implicate
AP1 factors in regulating E6}E7 expression in differentiating
epithelia.
Discussion
In the present study, we found that AP1 binding to the
HPV-31b LCR was reduced in C33A cells in which the HPV
enhancer was inactive and that enhancer activity was restored
when AP1 expression vectors were transfected. These findings
suggest that quantitative differences between AP1 levels in cell
types is a critical factor in determining enhancer tropism.
Previous studies have demonstrated an elevated level of AP1
in keratinocytes as compared to fibroblasts, possibly owing to
a lack of degrading enzyme resulting in increasing stability of
AP1 factors (Offord et al., 1993). The present EMSA analyses
also revealed that the predominant types of Jun that bind to
sites in the LCR varied in different cell types. Co-transfection
of the individual Jun proteins together with c-Fos into C33A
and HepG2 cells indicated the differential effect of each Jun
type on the HPV enhancer in different cell types. Thus,
differences between the Jun familymembers present in different
cell types may also contribute to enhancer tropism of HPV. It
has been suggested that AP1 interacts with some cellular
factors such as the glucocorticoid or retinoic acid receptors to
regulate gene transcription (de Groot et al., 1990 ; Jonat et al.,
1990 ; Schule et al., 1990). Such interactions could affect or alter
AP1 function in each cell type, also contributing to specificity
of HPV expression.
Previous studies on the expression of AP1 in differentiating
epithelia suggested that JunB expression was restricted to
differentiating cells (Wilkinson et al., 1989). In our study, JunB
as well as JunD were detected in the lower layers of stratified
epithelia in biopsies from normal cervix as well as low grade
CIN. c-Jun seemed to be more highly expressed in differen-
tiated layers. In contrast, in CIN III or invasive cervical cancer,
they were expressed throughout all layers. Studies by Welter
& Eckert (1996) using biopsies of normal foreskin keratinocytes
demonstrated JunB and JunD expression in most layers, while
c-Junwas found in the stratum granulosum. These observations
are similar but not identical to our studies ; this may be due to
the differences in tissue types.
Despite several studies examining E6}E7 expression in
uterine cervical lesions using in situ mRNA hybridization, some
confusion still exists concerning the distribution of E6}E7
transcripts in the differentiating epithelia. One of the major
reasons for this may be due to selection of probe sequences. As
previously described, E1–E4 differentiation-dependent tran-
scripts, which are expressed in the superficial cell layers of
differentiating epithelia, initiate at a promoter located within
the E7 ORF at nucleotide 742 in HPV-31 (Hummel et al., 1992)
and between 498 and 767 in HPV-16 (Higgins et al., 1992).
These late transcripts contain E7 sequences, although they do
not encode functional E7 proteins. Therefore, the use of probes
containing the entire E7 ORF would identify both early and
late transcripts. Another factor affecting the expression of early
genes in differentiating epithelia is the physical state of HPV
DNA, which can be episomal or integrated. The state of virus
DNA may vary among biopsy specimens and is sometimes
heterogeneous even in a sample, making correlations between
E6}E7 expression and cell differentiation difficult to inves-
tigate. To examine the expression of HPV genes in a
homologous population of cells, we utilized an in vitro
differentiation system with CIN612 cells derived from a CIN I
lesion, and found that E6}E7 transcripts were distributed
throughout the majority of the lower layers of the stratified
epithelia. This is consistent with our Northern blot analysis of
cells grown in monolayers and rafts, which indicated similar
levels of E6}E7 expression following stratification (Hummel et
al., 1992). Another study reported differentiation-independent
constitutive expression of HPV-16 E6}E7 using a monolayer
system in which CaSki cells were treated with calcium for
promoting cell differentiation (Choo et al., 1994). These
investigators observed that E6}E7 expression was not altered
by cell differentiation, further supporting the present results.
Our previous in situ hybridization studies indicated that HPV
genomes are amplified and late proteins are expressed in
differentiated cell layers (Bedell et al., 1991). These findings
together with the present results suggest that increasing the
copy number of virus genomes does not lead to elevated levels
of E6}E7 expression and that there may in fact be a reduction
in early transcription in cells that express late functions.
In contrast to E6}E7 expression, previous studies have
identified that L1, L2 and E1–E4 differentiation-dependent
transcripts are found in the suprabasal cell layers (Bedell et al.,
1991 ; Higgins et al., 1992 ; Hummel et al., 1992 ; Pray &
Laimins, 1995). Thus, E6}E7 and late gene expression appear
to be regulated by different mechanisms, which is not
surprising since late expression requires episomal templates
while early expression does not (Frattini et al., 1996). Although
the factors regulating the p742 promoter have not been
identified, it is possible that differentiation-dependent cellular
factors are involved in its regulation.
HPVs preferentially infect differentiating epithelia in genital
mucosa. Initial infection is thought to occur in the basal cell
layer where AP1 expression is significant. This pattern of AP1
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expression possibly promotes early gene expression, con-
tributing to the maintenance of initial infection and subse-
quently leading to replication in the upper layers. HPV
infection induces cell proliferation, which is probably owing to
specific interactions of the E6 and E7 products with p53 and Rb
proteins, respectively. It is also likely that elevated AP1
activity, which activates promoters of the genes involved in
cell proliferation, also contributes to the increased proliferation
ability of the cells. It thus appears that the coordinated action
of AP1 in inducing E6}E7 expression is important for
maintaining HPV-infected cells in a proliferation-competent
state during epithelial differentiation.
In conclusion, we have demonstrated that AP1 is a
significant regulator of HPV expression and that it contributes
to the specificity of virus expression in epithelial cells.
Expression of HPV-31b E6}E7 was observed throughout
lower layers of stratified epithelia and correlates with AP1
expression. This suggests a role for AP1 in regulating E6}E7
expression in differentiating epithelia.
We are grateful to all the members of the Laimins laboratory and Dr
Paolo Monini (University of Ferrara) for helpful advice and discussion.
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